{"id":"cefcapene","rwe":[{"pmid":"41792909","year":"2026","title":"Childhood Granulomatous Periorificial Dermatitis With Extrafacial Involvement.","finding":"","journal":"The Journal of dermatology","studyType":"Clinical Study"},{"pmid":"41523114","year":"2025","title":"Therapeutic outcomes of oral cefcapene in meibomitis-related keratoconjunctivitis: A Propensity-matched cohort study.","finding":"","journal":"Taiwan journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"40381916","year":"2025","title":"Antimicrobial susceptibility surveillance of bacterial isolates recovered in Japan from odontogenic infections in 2018.","finding":"","journal":"Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy","studyType":"Clinical Study"},{"pmid":"40190880","year":"2025","title":"Infectious Costochondritis With Sternal Osteomyelitis.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"39719740","year":"2025","title":"Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"}],"tags":[{"label":"cefcapene","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DD17","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cefcamate","offLabel":[],"synonyms":["cefcamate","cefcapene"],"timeline":[],"brandName":"Cefcamate","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cefcapene","explanation":"Imagine the bacterial cell wall as a strong, protective shield. Cefcapene blocks the enzymes that help build and repair this shield, causing the bacteria to weaken and eventually die. This allows the body's immune system to fight off the infection more effectively.","oneSentence":"Cefcapene works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Cefcapene exerts its antibacterial effects by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the transpeptidation reaction that cross-links peptidoglycan chains and maintains cell wall integrity."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4159","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFCAPENE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:18:27.052997","biosimilars":[],"competitors":[{"drugName":"cefotaxime","drugSlug":"cefotaxime","fdaApproval":"1981-03-11","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceftazidime","drugSlug":"ceftazidime","fdaApproval":"1985-07-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceftriaxone","drugSlug":"ceftriaxone","fdaApproval":"1984-12-21","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefmenoxime","drugSlug":"cefmenoxime","fdaApproval":"1987-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"latamoxef","drugSlug":"latamoxef","fdaApproval":"","relationship":"same-class"},{"drugName":"ceftizoxime","drugSlug":"ceftizoxime","fdaApproval":"1983-09-15","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefixime","drugSlug":"cefixime","fdaApproval":"1989-04-28","patentExpiry":"Dec 14, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cefpiramide","drugSlug":"cefpiramide","fdaApproval":"1989-01-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefoperazone","drugSlug":"cefoperazone","fdaApproval":"1982-11-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefpodoxime proxetil","drugSlug":"cefpodoxime-proxetil","fdaApproval":"1992-08-07","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceftibuten","drugSlug":"ceftibuten","fdaApproval":"1995-12-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefdinir","drugSlug":"cefdinir","fdaApproval":"1997-12-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefditoren pivoxil","drugSlug":"cefditoren-pivoxil","fdaApproval":"2001-08-29","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"cefcapene","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cefotaxime","brandName":"cefotaxime","genericName":"cefotaxime","approvalYear":"1981","relationship":"same-class"},{"drugId":"ceftazidime","brandName":"ceftazidime","genericName":"ceftazidime","approvalYear":"1985","relationship":"same-class"},{"drugId":"ceftriaxone","brandName":"ceftriaxone","genericName":"ceftriaxone","approvalYear":"1984","relationship":"same-class"},{"drugId":"cefmenoxime","brandName":"cefmenoxime","genericName":"cefmenoxime","approvalYear":"1987","relationship":"same-class"},{"drugId":"latamoxef","brandName":"latamoxef","genericName":"latamoxef","approvalYear":"","relationship":"same-class"},{"drugId":"ceftizoxime","brandName":"ceftizoxime","genericName":"ceftizoxime","approvalYear":"1983","relationship":"same-class"},{"drugId":"cefixime","brandName":"cefixime","genericName":"cefixime","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefpiramide","brandName":"cefpiramide","genericName":"cefpiramide","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefoperazone","brandName":"cefoperazone","genericName":"cefoperazone","approvalYear":"1982","relationship":"same-class"},{"drugId":"cefpodoxime-proxetil","brandName":"cefpodoxime proxetil","genericName":"cefpodoxime proxetil","approvalYear":"1992","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"4D5D3422MW","CHEBI":"CHEBI:131729","INN_ID":"7006","UMLSCUI":"C2699134","ChEMBL_ID":"CHEMBL582912","KEGG_DRUG":"D07638","DRUGBANK_ID":"DB13461","PUBCHEM_CID":"6436055","IUPHAR_LIGAND_ID":"12053"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":94,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DD17","allCodes":["J01DD17"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 6","pmid":"41792909","title":"Childhood Granulomatous Periorificial Dermatitis With Extrafacial Involvement.","journal":"The Journal of dermatology"},{"date":"2025 Oct-Dec","pmid":"41523114","title":"Therapeutic outcomes of oral cefcapene in meibomitis-related keratoconjunctivitis: A Propensity-matched cohort study.","journal":"Taiwan journal of ophthalmology"},{"date":"2025 Jul","pmid":"40381916","title":"Antimicrobial susceptibility surveillance of bacterial isolates recovered in Japan from odontogenic infections in 2018.","journal":"Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy"},{"date":"2025 Mar","pmid":"40190880","title":"Infectious Costochondritis With Sternal Osteomyelitis.","journal":"Cureus"},{"date":"2025 Jan","pmid":"39719740","title":"Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefcapene (CEFCAPENE) is a small molecule antibiotic belonging to the cefcapene class. It is a third-generation cephalosporin antibiotic, but its exact target and mechanism of action are not well-documented. The current owner of Cefcapene is not specified, and its commercial status, including FDA approval and off-patent status, is unknown. Further research is needed to determine its approved indications, half-life, and bioavailability.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}